Neuropilin-1 (NRP1) and NRP2 are cell-surface receptors shared by class 3 semaphorins and vascular endothelial growth factor (VEGF). Ligand interaction with NRPs selects the specific signal transducer, plexins for semaphorins or VEGF receptors for VEGF, and promotes NRP internalization, which effectively shuts down receptor-mediated signaling by a second ligand. Here, we show that the sulfated polysaccharides dextran sulfate and 
Introduction
Coordinate development of the vascular system and adult angiogenesis are regulated by endothelial cell surface receptors activated by soluble mediators [1] [2] [3] , and by insoluble mediators bound to cells or extracellular matrix [4] [5] [6] . Neuropilin-1 (NRP1) and NRP2 are endothelial cell receptors shared by members of the class 3 semaphorin and VEGF families [7] [8] [9] [10] [11] , serving as "hubs" for different ligands. Thus, NRP1 can bind semaphorin3A (Sema3A), 3B, 3C, heparin-binding forms of VEGF-A, VEGF-B and placenta growth factor-2 (PlGF2); and NRP2 can bind Sema3B, 3C, 3F, VEGF-A, VEGF-C and VEGF-D 10, 12 . Structurally, NRP1 and NRP2 have an extracellular, a single transmembrane and a short cytoplasmic domain 10, 11 . Within the NRP1 extracellular domain, 3 subdomains were identified: the a1/a2 (CUB) domain at the N-terminus with homology to complement components, followed by the b1/b2 (coagulation factor V/VIII) domain and the c (C-terminal MAM) domain 13 . Sema3A binds to the a1/a2/b1 domains, whereas VEGF-A binds to the b1/b2 domain 14, 15 .
Previous studies have shown that NRP1 uses the VEGF receptor 2 (VEGFR-2) to transduce VEGF 165 signals 16 and plexin-A1, -A2 or -A4 to transduce Sema3A signals [17] [18] [19] , and that NRP1 can orderly mediate signals by these different ligands by complex mechanisms, including internalization [20] [21] [22] . NRP1-null mice are embryonically lethal, and display severe abnormalities in the nervous and cardiovascular systems 23 . NRP2-deficient mice display defective retinal neovascularization in response to ischemia 24 .
Mice lacking both NRP1 and NRP2 are more severely affected than mice lacking only NRP1 25 . In adult mice, monoclonal antibodies against NRP1 inhibit angiogenesis and 26 . These observations point to a critical role of NRP1 and NRP2 in angiogenesis.
The b1/b2 extracellular subdomain of NRP1 has heparin-binding capacity 14, 27 . Heparin enhances the binding of Sema3A and VEGF 165 to NRP1 and augments their biological functions 9, 21, 28, 29 . Many glycosaminoglycans and sulfated polysaccharides can bind to a variety of proteins and lipoproteins in mammalian tissues and modulate their function 30 . Heparin can bind to low density lipoprotein (LDL) and compete for LDL binding to LDL receptors 30 . Fucoidan and dextran sulfate, but not heparin, are ligands for acetylated-LDL (Ac-LDL) receptors and can compete for Ac-LDL binding to Ac-LDL receptors [31] [32] [33] [34] .
Cell surface receptors for Ac-LDL and other chemically-modified lipoproteins, defined as scavenger receptors, are uniformly expressed on macrophages 31, 35 and to a lower extent on endothelial cells and selected endothelial progenitor cells 36, 37 .
Endothelial cell-associated scavenger receptors include CD36, also identified as scavenger receptor class B type I (SR-BI), lectin-like oxidized LDL receptor-1 (LOX-1), collectin placenta 1 (CL-P1), FEEL-1/Stabilin-1/CLEVER-1, and scavenger receptor expressed by endothelial cells I (SREC-I) and II 38, 39 . In addition to binding to Ac-LDL and oxidized-LDL, scavenger receptors can bind structurally different ligands, including selected sulfated polysaccharides. Endothelial scavenger receptors have been implicated in the pathogenesis of atherosclerosis, but their roles in angiogenesis are not clear 34, 40, 41 .
Taking advantage of endothelial cell expression of both scavenger receptors and NRP1, we show here that certain sulfated polysaccharides mediate the bridging of NRP1
to scavenger receptors, and promote the internalization of cell-surface NRP1 resulting in 
NRP1-heparin binding assay
Heparin was biotinylated as described previously 43 . Biotinylated heparin (1.8 U/ml in PBS) was injected onto the flow cell of the Sensor Chip SA (Biacore, Piscataway, NJ).
500 resonance units (RUs) of biotinylated heparin were immobilized. NRP1-heparin binding was analyzed by using the BIAcore 3000 system (Biacore). NRP1/Fc protein (20 nM) was diluted in HEPES buffer saline containing 0.005% Surfactant P20 (HBS-P, Biacore) injected over the heparin-coated or control flow cell surface at a flow rate 50
µl/min at 25°C. Association and dissociation phases were evaluated for 2 min. The sensor chip was regenerated with pulse of 2 M NaCl for 30 s. The data was analyzed using BIAevaluation software (Biacore).
Affinity purification with immobilized polysaccharide gels
NRP1/Fc or gp130/Fc were incubated with heparin-gel, dextran sulfate-gel or maltose-gel (EY Laboratories, San Mateo, CA) at 25°C for 1 h. After washing with PBS (x3), gels were suspended in tricine SDS sample buffer (Invitrogen), and incubated at 100°C for 5 min. Extracts were separated by SDS-PAGE, transferred onto nitrocellulose membrane (Invitrogen), blocked with 5% skim milk in PBS 0.1% Tween20, and immunostained using biotin-conjugated anti-human IgG1 Ab (Zymed, South San Francisco, CA), followed by incubation with a HRP conjugated streptavidin (Zymed). Immunocomplexes
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Flow cytometric analysis
HUVEC were detached with 5 mM EDTA in PBS, washed with 1% FBS buffer (MEDIUM199, 1% FBS, 10 mM HEPES), and incubated with polysaccharides. After rinsing (x2) with 1M NaCl with 0.2% BSA followed by binding buffer (x2), cells were stained with PE-anti-BDCA-4 (NRP1) mAb (AD5-17F6; Miltenyi Biotec, Auburn, CA), PE-anti-VEGFR-1 mAb (49560; R&D Systems), PE-anti-VEGFR-2 mAb (89106; R&D Systems), FITC-anti-CD31 mAb (WM59; BD Biosciences, San Jose, CA), PE-anti-VEcadherin mAb (123413; R&D Systems), PE-anti-CXCR4 mAb (2B11; BD Biosciences), or anti-NRP2 mAb (C-9; Santa Cruz Biotechnology, Santa Cruz, CA), anti-gp130 mAb (AM64; BD Biosciences) or anti-SREC-I Ab (AF2409; R&D Systems) followed by Alexa 488-conjugated anti-mouse Ab or Alexa 488-conjugated anti-goat Ab (Invitrogen).
Data were collected using a FACScalibur cytofluorometer (BD, Franklin Lakes, NJ).
Laser confocal microscopy
Endothelial cells growing onto glass chamber slides (Nalge Nunc International, Rochester, NY) coated with 5 µg/ml fibronectin were incubated in 1% FBS buffer with DS500 (8 µg/ml) and protease inhibitor cocktail III (Calbiochem) at 37°C for the indicated times. The medium was replaced with 4% wt/vol paraformaldehyde for fixation, cells were washed with PBS, and permeabilized with 0.1% Triton X100 in PBS.
Cells were then stained with mouse anti-human NRP1 mAb, rabbit anti-human Lamp1 
Western blot analysis
After incubation of endothelial cells in 1% FBS buffer with 2 µg/ml of DS500, cell pellets were suspended in lysis buffer (0.5% NP40, 150 mM NaCl, 10 mM TrisHCl pH 7.4) with protease inhibitor cocktail III. Cell lysates were separated by SDS-PAGE, transferred onto nitrocellulose membranes, and immunostained using rabbit anti-NRP1 Ab (Santa Cruz Biotechnology), followed by incubation with an HRP-conjugated antirabbit IgG Ab (GE Healthcare). Immunocomplexes were visualized using a chemiluminescence detection system. The membrane was re-blotted with goat anti-actin Ab (Santa Cruz Biotechnology). Band intensities were measured by NIH image.
Forced expression of SREC-I and NRP1
Human NRP1 in pCMV6-XL4 was from OriGene Technologies (Rockville, MD).
Human SREC-I in pCMV-SPORT6 was from Open Biosystems (Hunstsville, AL). 
Cell binding assays
HUVEC were incubated in 1% FBS buffer with or without polysaccharides. Cells were washed with 1M NaCl twice, followed by washing with 1% FBS buffer. Cells were incubated with Sema3A/Fc (2 µg/ml) or biotinylated VEGF 165 (100 ng/ml) (R&D Systems) in 1% FBS buffer with 2µg/ml heparin at 0°C for 1 h. Sema3A/Fc or biotinylated VEGF 165 bound to cells was detected with FITC-conjugated F(ab') 2 goat anti-human IgG Fc (Jackson ImmunoResearch Laboratories, West Grove, PA) or Avidin-FITC (R&D Systems). Data were collected using a FACScalibur cytofluorometer.
Endothelial cell retraction assay
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From HUVEC were incubated in 1% FBS buffer with or without DS500 (2 µg/ml) or Fucoidan (8 µg/ml) at 37°C for 1 h. After washing (x3) with assay medium (1% FBS buffer with 2 µg/ml heparin), HUVEC (16,000 cells/chamber) were added to the four-chamber glass slides pre-coated with 5 µg/ml fibronectin. After 1 h, cells were stimulated with Sema3A (2 µg/ml, 1 h). After fixation with 4% wt/vol paraformaldehyde, four non-overlapping fields were observed to obtain an average retraction score, as described 21 .
Endothelial cell proliferation assay
HUVEC (2,000 cells/well) were cultured 3 d in 96-well tissue culture plates (Corning) in MEDIUM199 with 10% FBS and 25 µg/ml heparin, with or without 25 ng/ml of VEGF 165 . Proliferation was measured by 3 H thymidine uptake (0.6 µCi/well, New England Nuclear) during the last 16 h of culture.
In vivo Matrigel and tumor angiogenesis assays
All animal experiments were approved by the NCI-Bethesda Animal Care and Use
Committee. The Matrigel assay was performed essentially as described 44 
Statistical analysis
Results are expressed as means ±SD or SEM. Student's t-test was applied to evaluate group differences; a p-value of < 0.05 was considered significant.
Results

Analysis of NRP1 binding to polysaccharides
Heparin binds to the extracellular domain of NRP1 within the b1/b2 sub-domain 15, 27 . We examined whether other polysaccharides can bind to NRP1. Using surface plasmon resonance (Biacore system), we confirmed that recombinant NRP1 extracellular domain dose-dependently binds to a heparin-coated sensor chip (not shown). On the basis of the results of 3 experiments, the Kd for the NRP1-heparin interaction was calculated at 0.69±0.13 nM (association rate constant (ka) 5.7±1.1x10 6 . Heparin-and maltose-gel were used as controls for DS-gel, and gp130/Fc was used as a control for NRP1/Fc. We affinity purified abundant NRP1/Fc from heparin-gel and DS-gel, but only little from control maltose-gel.
We could not elute gp130/Fc from these gels ( Figure 1B ). These experiments demonstrate that DS directly binds to NRP1.
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Effects of DS500 and Fucoidan on cell-surface NRP1
Heparin binds to cell-surface NRP1 and enhances the biological activity of VEGF 165 and Sema3A 15, 29 . We now tested whether DS500 and Fucoidan can also bind to cell-surface NRP1 and modulate its function. Primary human umbilical vein endothelial cells (HUVEC) were incubated with each of the polysaccharides tested in Figure 1A at 37°C for 1 h, and after washing with 1M NaCl (which effectively removes NRP1 from heparin as assessed by Biacore), we measured levels of cell-surface NRP1 by flow cytometry. As shown in Figure 1C , DS500 and to a lower degree Fucoidan reduced NRP1 levels on HUVEC, but all other polysaccharides, including heparin, did not. By the same method, DS500 reduced cell-surface NRP2 and to a lower extent VEGFR-1 and VEGFR-2, but minimally reduced cell-surface CD31, VE-cadherin, gp130 or CXCR4 ( Figure 1D ), indicating that DS500 does not indiscriminately alter detection of cell-surface molecules.
Similar results were derived with Fucoidan (not shown). We examined the conditions for reduction of cell-surface NRP1 and NRP2 by DS500 ( Figure 1E ). At 37°C, but not at 0°C, DS500 dose-dependently reduced cell-surface NRP1 and NRP2, with maximal inhibition at 2 µg/ml and ED 50 of 1.0±0.13 µg/ml (2.0±0.26 nM) (average of three experiments). This reduction occurred progressively over 90 min. Thus, DS500 reduces cell-surface NRP1 and NRP2 on endothelial cells in a temperature, concentration and time-dependent manner. By using fluorescence microscopy, we confirmed visually that cell-surface NRP1 is reduced on HUVEC after 1 h incubation with DS500 (8 µg/ml) at 37°C compared to control cells incubated in medium only ( Figure 1F , representative images). Since several serum components are known to interact with 30 , we examined the effect of human serum on the reduction of cellsurface NRP1 by DS500. As shown in Figure 1G , DS500 dose-dependently reduced cellsurface NRP1 on HUVEC in the presence of 95% human serum and the reduction was similar to that achieved in the presence of 1% human serum. Thus, DS500 reduces cellsurface NRP1 on endothelial cells even in the presence of high serum concentrations.
DS500 and Fucoidan promote the internalization of cell-surface NRP1
We next examined whether DS500 and Fucoidan promote the internalization of NRP1;
this would explain why cell-surface NRP1 is detected at lower levels after incubation with these polysaccharides. Using confocal microscopy, we traced NRP1 in endothelial cells after 10-60 min incubation with DS500 (8 µg/ml) at 37°C. At time 0, NRP1 is minimally detectable in HUVEC that have been fixed and permeabilized. After 10 min, NRP1 staining is visible at low levels and becomes progressively more intense. After 60 min, NRP1 is clearly identified by a vesicular-like staining (Figure 2A) , and co-localizes with Lamp1 (lysosome associated membrane protein-1) ( Figure 2B ). Similar results were obtained with Fucoidan (not shown). These observations demonstrated that DS500
promotes NRP1 internalization and trafficking to the lysosomal compartment. Westernblot analysis of endothelial cell lysates showed that the intensity of the NRP1-related band decreases after incubation with DS500 longer than 30 min ( Figure 2C ), suggesting that NRP1 is degraded in the lysosomes. Together, these results demonstrate that DS500 promotes NRP1 internalization from the cell-surface to the cytoplasm where it reaches the lysosome and is degraded.
DS500 and Fucoidan promote the internalization of cell-surface SREC-I
We investigated the mechanisms underlying NRP1 internalization induced by DS500.
First, we tested whether binding of DS500 to cell-surface NRP1 is sufficient for internalization. Besides HUVEC, NRP1 is detected on the human leukemia RS4 and the human stromal HS-5 cell lines, and on COS7 cells transduced with human NRP1 (COS7-NRP1) ( Figure 3A) . DS500 dose-dependently reduced cell-surface NRP1 on HUVEC, but failed to do so on RS4, HS-5 or COS7-NRP1 cells ( Figure 3B ), indicating that NRP1 internalization by DS500 requires additional critical components, which are present in HUVEC but not in the other cell types tested. One of the parameters that we found distinguishes HUVEC from RS4, HS-5 and COS7-NRP1 is expression of scavenger receptors, which mediate the uptake of LDL modified by acetylation or oxidation. Some of the scavenger receptors are known to interact with sulfated polysaccharides [32] [33] [34] . As shown in Figure 3C , HUVEC displayed a dose-dependent uptake of DiO-Ac-LDL, whereas RS4, HS-5 and COS7-NRP1 displayed only minimal uptake. Unlabeled Ac-LDL blocked uptake of DiO-Ac-LDL in HUVEC, indicating the Ac-LDL specificity of DiO-Ac-LDL uptake in these cells.
Several scavenger receptors have been identified in endothelial cells 32 . We focused on SREC-I (scavenger receptor expressed by endothelial cells-I), as it is highly expressed on HUVEC, and examined whether SREC-I can mediate the uptake of Ac-LDL in HUVEC. By confocal microscopy, we found that Ac-LDL promotes the intracellular accumulation of SREC-I (green) ( Figure 4A , upper panels), and that internalized SREC-I (green) and Ac-LDL (red) co-localize (yellow) at least in part within HUVEC ( Figure 4A , lower panels). This provides evidence that SREC-I can mediate the
uptake of Ac-LDL in HUVEC, and that SREC-I itself is internalized after binding to its ligand.
Certain sulfated polysaccharides can bind to selected scavenger receptors and block Ac-LDL uptake [32] [33] [34] . We therefore examined whether DS500, Fucoidan and other sulfated polysaccharides could serve as ligands for SREC-I. Using FACS analysis for detection of cell surface SREC-I, we found that DS500 and to a lower degree Fucoidan reduced cell-surface SREC-I in HUVEC when incubated for 1 h at 37°C, whereas heparin, HS, ChoSul A, ChoSul B, ChoSul C and non-sulfated dextran did not ( Figure   4B ). VEGF 165 
permeabilization, we found that DS500 and Fucoidan, but not heparin or ChoSul A, promoted the internalization of SREC-I and NRP1, and importantly, we found that internalized NRP1 and SREC-I co-localize in structures ( Figure 5A , right panels, yellow), which we have identified as lysosomes ( Figures 2B and 4E) . We tested directly whether DS500 can bridge SREC-I and NRP1 by using an ELISA-based assay in which SREC-I/Fc or control IgG1 is immobilized onto the well and NRP1/Fc is then added with DS500 at varying concentrations. As shown in Figure 5B , we found that DS500 dose- Among the polysaccharides tested, DS500 and to a lower degree Fucoidan promoted NRP1 binding to SREC-I, whereas the other polysaccharides were minimally effective ( Figure 5C ). Together, these results indicate that DS500 and Fucoidan can bridge NRP1 to SREC-I, and induce their coordinate internalization from the endothelial cell-surface to the cytoplasm where NRP1 and SREC-I co-localize.
To further define the role of SREC-I in NRP1 internalization, we expressed SREC-I in human 293 cells, which do not express endogenous scavenger receptors, but express gp130, CXCR4 and NRP1. As shown in Figure 5D , control 293 cells did not uptake DiO-Ac-LDL, but 293-SREC-I cells could uptake DiO-Ac-LDL, indicative of
SREC-I function (upper left). An analysis of cell-surface gp130, CXCR4 and NRP1
showed that levels of gp130 (upper right) and CXCR4 (lower left) were similar in control spread lamellipodia when placed onto a fibronectin-coated glass surface, and Sema3A is known to induce retraction of these lamellipodia 21 . We found that Sema3A induces minimal retraction of lamellipodia in HUVEC that were pretreated with DS500 or Fucoidan, indicative that these polysaccharides can block this function of Sema3A ( Figure 6B ). We scored the degree of retraction in 3 independent experiments, as described 21 , and found that DS500 and Fucoidan reduce significantly Sema3A-induced lamellipodia retraction in HUVEC ( Figure 6C ). We also found that pretreatment with DS500 dose-and time-dependently blocked the binding of VEGF 165 
to HUVEC, whereas
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Thus, DS500, Fucoidan, heparin, ChoSul A, and dextran have parallel effects on the binding of Sema3A and VEGF 165 to HUVEC (Figures 6A,D) . We examined the effects of polysaccharides on VEGF 165 -induced proliferation of endothelial cells. As shown in Figure 6E , DS500 and to a lower degree Fucoidan inhibited HUVEC proliferation in response to VEGF 165 , whereas ChoSul A was minimally effective.
Fucoidan inhibits angiogenesis in vivo
We tested the effects of Fucoidan and DS500 on VEGF-induced angiogenesis in vivo.
To this end, we established subcutaneous (s.c.) Matrigel plugs containing VEGF (150 ng/ml) plus heparin (0.5 µg/ml) or PBS alone in mice (C57BL/6J 7 weeks old), and then treated groups of these mice (5 mice/group) intraperitoneally (i.p.) with Fucoidan, DS500 or dextran (all at 1 mg/mouse) daily for 6 days beginning on the day of Matrigel injection. DS500 treatment induced death in 8/10 animals; Fucoidan and dextran were well tolerated. All plugs were removed from the mice on day 7 and processed for histology and immunohistochemitry (CD31/PCAM staining). The endothelial cell density (measured digitally with IP-lab software) was significantly (P=0.003) reduced in VEGF-supplemented plugs from mice treated with Fucoidan compared to Dextran ( Figure 7A ). Plugs without VEGF supplementation displayed minimal cell infiltration with or without systemic treatment (not shown). In a repeat experiment using BALB/cAnNCr mice (6-weeks old; 6 mice/group), we confirmed that Matrigel plugs from the Fucoidan-treated group contained a significantly (P<0.001) reduced endothelial 
Discussion
We show that the sulfated polysaccharides dextran sulfate and Fucoidan reduce endothelial cell surface levels of NRP1, NRP2 and to a lower extent VEGFR-1 and VEGFR-2, and block the binding and function of Semaphorin3A and VEGF 165 . We find that dextran sulfate and Fucoidan can bridge the extracellular domain of NRP1 to that of the scavenger receptor SREC-I, and promote their coordinate internalization in endothelial cells. These results provide evidence that certain polysaccharides can induce internalization of selected cell surface receptors, and delineate a strategy for dampening cell responses to undesired specific ligands.
Internalization is one of the mechanisms by which cell surface receptors attenuate ligand-induced signaling. After a ligand binds to its receptor on the cell membrane, a signal is generated and the receptor is internalized. This sequestration of the receptor away from the cell surface often results in ligand desensitization and protection from prolonged or excessive signaling [47] [48] [49] . In the case of shared-type receptors, i.e. when the same cell surface molecule is a receptor for distinct ligands, internalization of the receptor induced by one ligand can serve to block receptor binding by the second ligand.
CXCR4 and CCR5 are chemokine receptors, which also serve as co-receptors for HIV-1 facilitating viral entry into target cells. SDF-1, RANTES and some variants of these chemokines, which bind to their respective cognate CXCR4 and CCR5 receptors and induce their internalization, can inhibit HIV infection [50] [51] [52] . NRP1 and NRP2 are receptors shared by VEGF members and class 3 semaphorins. VEGF-induced internalization of NRP1 or NRP2 prevents the binding of Sema3A or Sema3F 21, 22 . These examples are analogous to polysaccharide-induced NRP1 internalization described here, which can
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block the binding of NRP1 ligands Sema3A and VEGF 165 . Internalization of NRP1 by the sulfated polysaccharides required the presence of a scavenger receptor, which can be viewed as a necessary driver for NRP1 internalization. This is analogous to VEGFinduced internalization of NRPs, which requires VEGFRs 21, 22 . SREC-I binds Ac-LDL, Fucoidan and Dextran sulfate 39 . We now found that DS500 and Fucoidan promote internalization and trafficking of SREC-I to the lysosome.
We also found that SREC-I internalization, induced by these polysaccharides, is accompanied by internalization of NRP1, and that these two receptors are subsequently For
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NRP1 neutralization by antibodies or by a soluble form of NRP1 was previously shown to inhibit tumor angiogenesis and tumor growth in vivo 26, 54 . In one study, Fucoidan displayed anti-angiogenic and anti-tumor activity in vivo, but the underlying mechanisms were not elucidated 55 . We have confirmed here that Fucoidan inhibits VEGF-induced and tumor angiogenesis in vivo, and provide evidence that reduction of cell surface NRP1, NRP2 and other VEGF receptors contribute to these effects.
Reduction of surface molecules not tested here and other factors may contribute to the anti-angiogenic effects of polysaccharides. Fucoidan was reported to induces mobilization of stem/progenitor cells, which was attributed to competitive displacement of SDF-1 from heparan sulfate proteoglycans 56 , and the sulfated polysaccharides heparin and heparan sulfate were reported to have anti-inflammatory activity, which was attributed to blockade of P-and L-selectin-mediated cell adhesion 57, 58 . SREC-I (green), Lamp1 (red) and DAPI (blue) were examined by confocal microscopy in HUVEC incubated with DS500 (8 µg/ml, 37°C, 1 h), fixed and permeabilized. For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
